29.08.2021, 2943 Zeichen

UBM: Real estate developer UBM generated Total Output of Euro 237.3 mn in the first half of 2021, compared with Euro 181.3 mn in the comparable prior year period. EBT declined year-on-year to Euro 35.7 mn (H1/2020: Euro 43.8 mn), but UBM recorded the highest net profit in its history at Euro 27.5 mn (H1/2020: Euro 26.6 mn). The sound first half-year results and sales activity expected over the coming months make it possible for UBM to issue a guidance for the 2021 financial year: “Instead of the previously announced “corona dip”, we now expect an EBT of Euro 55 mn to Euro 60 mn” says UBM CEO Thomas G. Winkler “and with the sale of several projects prior to the start of construction, we successfully steered through these challenging times.”
UBM: weekly performance: 4.22%

Marinomed: Due to strong demand in Marinomed’s Carragelose-based virus blockers, revenues of the Company increased by 41% to Euro 3.2 mn (H1 2020: Euro 2.3 mn), supported by positive scientific and clinical data on the anti-SARS-CoV-2 activity of Carragelose-based products. Due to increased R&D expenses of Euro 4.3 mn (H1 2020: Euro 2.2 mn) for the two technology platforms, Carragelose and Marinosolv, the operating result (EBIT) decreased to Euro -3.6 mn (H1 2020: Euro -2.9 mn), which is in-line with Marinomed’s business plan. Net loss for the period was Euro 4.4 mn compared to Euro 3.2 mn in H1 2020. “We are pleased about the strong growth in the first half of the year. Carragelose products gained market share in many markets and while pharmacies reported declining sales in the cough and cold segment, sales of Carragelose products increased. However, with the pandemic moving into a more endemic phase, we expect the return of the typical seasonality of sales. Going forward, we plan to further extend our clinical activities and to slightly increase R&D spending compared to 2020. R&D will focus more on Marinosolv again, as this segment has significant untapped potential,” said Pascal Schmidt, CFO of Marinomed.
Marinomed Biotech: weekly performance: -0.45%

CA Immo: Real estate company CA Immo recorded a 1.5% increase in rental income to Euro 119.9 mn in the first six months. This positive development is related to the portfolio growth of the past quarters. FFO I, key indicator for the sustainable earnings power of the Group, which is reported before tax and adjusted for the sales result and other non-sustainable effects, stood at Euro 68.5 mn (30.6.2020: Euro 68.2 mn). CA Immo had an almost complete external valuation of the portfolio carried out as at 30 June 2021. The result is a significantly higher revaluation result of Euro 195.3 mn compared to the previous year (30.6.2020: Euro –27.0 mn). The consolidated net profit of Euro 171.3 mn was substantially higher than the previous year's figure of Euro 44.7 mn.
CA Immo: weekly performance: -0.14%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/08/2021)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S14/15: Ricardo-José Vybiral

Bildnachweis

Aktien auf dem Radar:Rosenbauer, SBO, Polytec Group, Austriacard Holdings AG, Addiko Bank, Strabag, Zumtobel, Porr, Bawag, Rosgix, Telekom Austria, AT&S, CA Immo, Erste Group, ams-Osram, BTV AG, Marinomed Biotech, Pierer Mobility, Oberbank AG Stamm, Agrana, Amag, EVN, Flughafen Wien, Immofinanz, Palfinger, Österreichische Post, RHI Magnesita, S Immo, Uniqa, VIG, Wienerberger.

---